Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical ... new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... that will increase healthcare worker safety and reduce financial costs. , CTI Electronics ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... July 8 Knowledge Enterprises, Inc.,and The ... of The,2007-2008 Orthopaedic Industry Annual Report, the ... data. The nearly 200,page Annual Report summarizes ... Joint Replacement, Fracture Repair, Arthroscopy/Soft,Tissue Repair, Spinal ...
... 8 Telik, Inc.,(Nasdaq: TELK ), today ... Chemistry Letters describing a novel class of small ... treatment for diabetes.,These unique compounds are the result ... optimize the original lead structure identified through,the application ...
... US-made bulk API, BATON ROUGE, La., ... (NYSE: ALB ), a leading global ... active pharmaceutical,ingredients (APIs), has signed a global ... As per the agreement, effective,immediately, Albemarle has ...
Cached Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... with the gradual acidification of the world,s oceans than previously ... escape climatic devastation. In new research published in the ... has identified a powerful internal mechanism that could enable some ... of a more acidic ocean. As humans release ever-larger ...
... , Radioactive iodine found by Dartmouth researchers in the ... a nuclear reactor,s explosion and meltdown half a world ... Department of Earth Science. The failure of the Fukushima ... earthquake and tsunami, was the largest nuclear disaster since ...
... be no accident when doctors observe how patients suffering ... more aggressive cancer. However, the new-found interaction between the ... A potential relationship between metastatic breast cancer and ... led researchers from the University of North Carolina at ...
Cached Biology News:Corals 'could survive a more acidic ocean' 2Corals 'could survive a more acidic ocean' 3Dartmouth scientists track radioactive iodine from Japan nuclear reactor meltdown 2Dartmouth scientists track radioactive iodine from Japan nuclear reactor meltdown 3Mechanism found connecting metastatic breast cancer and arthritis 2Mechanism found connecting metastatic breast cancer and arthritis 3
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: